Startups

Director of Business Development – CMC (Ajinomoto Bio-Pharma Services)

Forge Biologics · Columbus, Ohio · On-site

← All jobs
About Forge Biologics

Forge Biologics is a gene therapy development engine, focused on enabling access to life-changing gene therapies and helping bring them from an idea into reality. Backed by Drive Capital.

About the role

As a vital member of the Client Development department, the Director of Business Development drives strategic growth by generating high-value partnerships for our innovative AJIPHASE® platform-based oligonucleotide and peptide CDMO business within Ajinomoto Bio-Pharma Services.

What they're looking for

  • Bachelor’s degree in a life sciences field (e.g., Chemistry, Biochemistry, Biotechnology) or a business degree paired with substantial technical pharmaceutical experience
  • 3–5 years of dedicated experience in Business Development
  • 3+ years of hands-on experience with CMC at a pharmaceutical or biotech company, or in a CMC support role at CDMO company
  • Demonstrated familiarity with high-level CRM data architecture and technical CMC documentation workflows
  • Experience collaborating across global time zones
  • Ability and willingness to travel domestically between 25-50% of the time, along with international travel to Japan approximately 2-3 times per year
More about this role

Ajinomoto Co., Inc. is a global leader in amino acid science, biotechnology, and healthcare, with an expanding global presence in biopharmaceutical development and contract manufacturing. Through Ajinomoto Bio-Pharma Services, the company combines decades of scientific and manufacturing expertise in Japan with an international network serving innovative pharmaceutical and biotechnology partners.

At the heart of this opportunity is AJIPHASE®, Ajinomoto's proprietary hybrid solid/solution-phase synthesis technology for manufacturing high-purity oligonucleotides and peptides. AJIPHASE® offers a proven, highly scalable approach to complex synthesis — from milligram quantities to over 200 kg — with an established track record supporting FDA-approved commercial drug products under cGMP conditions. AJIPHASE® sits alongside Ajinomoto's broader portfolio of proprietary technologies, including CORYNEX® (microbial protein and peptide expression) and AJICAP® (site-specific ADC technology), reflecting the company's continued investment in advancing biopharmaceutical manufacturing.

This position offers a unique commercial opportunity to bring a highly differentiated, proprietary Japanese...

Read the full posting on Forge Biologics's site ↗

Client Development

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.